

SUPPLEMENTARY PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 63 of the European Patent Convention EP 03 79 9822 shall be considered, for the purposes of subsequent proceedings, as the European search report

	DOCUMENTS CONSID	ERED TO BE RELEVANT		
Category	Citation of document with in of relevant pass	ndication, where appropriate, ages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Α	US 6 426 074 B1 (MI 30 July 2002 (2002- * the whole documer	07-30)	1-17	INV. A61K6/00
				TECHNICAL FIELDS SEARCHED (IPC)
				A61K
The su	upplementary search report has b d available at the start of the sea	een based on the last set of claims val	lid	1
	MPLETE SEARCH			1
not compl be carried Claims se		application, or some or all of its claims, does a meaningful search into the state of the art ly, for the following claims:		
Claims no	ot searched :			
Reason fo	or the limitation of the search:			
	sheet C			
	Place of search	Date of completion of the search		Examiner
	The Hague	21 January 2008	Mo	reau, Jean-Marie
C	ATEGORY OF CITED DOCUMENTS	T : theory or princip E : earlier patent do		
Y : part	icularly relevant if taken alone icularly relevant if combined with anot	after the filing d	ate I in the application	
A : tech	ıment of the same category nological background -written disclosure			v corresponding
	rmediate document	document	same patent lamii	y, corresponding



INCOMPLETE SEARCH SHEET C

Application Number EP 03 79 9822

Although claim 16 is directed to a method of treatment of the human/animal body (Article 53(c) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 03 79 9822

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

21-01-2008

cited	atent document d in search report		Publication date		Patent family member(s)		Publication date
US	6426074	B1	30-07-2002	US	2003035805	A1	20-02-2003
			ficial Journal of the Euro				

PATENT COOPERATION TREATY

PCT

REC'D 1 4 MAR 2005

INTERNATIONAL PRELIMINARY EXAMINATION REPURIFO

PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		See Notification	of Transmittal of International		
PP19766.002	FOR FURTHER ACTION		amination Report (Form PCT/IPEA/416)		
International application No.	International filing date (day/mon	th/year)	Priority date (day/month/year)		
PCT/US03/29167	15 September 2003 (15.09.2003)		15 September 2002 (15.09.2002)		
International Patent Classification (IPC) or national classification and IPC					
IPC(7): A61K 39/385, 39/02, 39/09, 39/00 and US Cl.: 424/197.11, 234.1, 244.1, 184.1, 236.1, 831					
Applicant					
CHIRON CORPORATION					
Examining Authority and i	ary examination report has been is transmitted to the applicant ac a total of	cording to Artic	s International Preliminary le 36.		
2. This real consists of a	a total ofslicets, including th	ns cover sheet.			
which have been amen	This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).				
These annexes consist of a	total of sheets.				
This report contains indicate	tions relating to the following ite	ems:			
I Basis of the repo	ort				
II Priority					
	ent of report with regard to novel	ltv. inventive etc	an and industrial applicability		
		ity, inventive sic	p and industrial applicationity		
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement					
VI Certain documents cited					
VII Certain defects in the international application					
VIII Certain observations on the international application					
Contact of the international application					
Date of submission of the demand		of completion of			
129pril 2004 (12,04,2004)		march 20	25 (05.03,2005) Bell-Harris fin		
Name and mailing address of the IPEA/US	Aut	ized officer	7000		
Mail Stop PCT, Attn: IPEA/ US Commissioner for Patents P.O. Box 1450	S. Diek	alerie	Self-Harris An		
Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230	Telepho	one No. CE:7/	0272-1600		
Facsimile No. (703)305-3230 Telephone No. (45/7/)272-/600					

Form PCT/IPEA/409 (cover sheet)(July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US03/29167

I.	Bas	sis of the report
1.	With	h regard to the elements of the international application:*
	\boxtimes	the international application as originally filed.
	\boxtimes	the description:
ĺ		pages 1-31 as originally filed
		pages NONE, filed with the demand pages NONE, filed with the letter of
	\boxtimes	the claims:
	اخسكا	pages <u>32-34</u> , as originally filed
1		pages NONE , as amended (together with any statement) under Article 19
		pages NONE, filed with the demand pages NONE, filed with the letter of
		the drawings:
	لــــن	pages <u>NONE</u> , as originally filed
		pages NONE, filed with the demand
		pages NONE, filed with the letter of
		the sequence listing part of the description:
		pages <u>NONE</u> , as originally filed pages <u>NONE</u> , filed with the demand
		pages NONE, filed with the letter of
2.	lang	h regard to the language , all the elements marked above were available or furnished to this Authority in the guage in which the international application was filed, unless otherwise indicated under this item. se elements were available or furnished to this Authority in the following language which is:
		the language of a translation furnished for the purposes of international search (under Rule23.1(b)).
Į	Ħ	the language of publication of the international application (under Rule 48.3(b)).
ı		the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).
3.	With inter	n regard to any nucleotide and/or amino acid sequence disclosed in the international application, the mational preliminary examination was carried out on the basis of the sequence listing:
		contained in the international application in printed form.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority in written form.
		furnished subsequently to this Authority in computer readable form.
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
		The statement that the information recorded in computer readable form is identical to the written sequence listing
		has been furnished.
4.		The amendments have resulted in the cancellation of:
		the description, pages NONE
		the claims, Nos. NONE
		the drawings, sheets/fig NONE
5.		This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
	Replace repor	rement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in rt as "originally filed" and are not amexed to this report since they do not contain amendments (Rules 70.16 and 70.17). Eplacement sheet containing such amendments must be referred to under item 1 and annexed to this report.
	DCT	(IDE A //00 / Dev. D. / Index 1000)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US03/29167

Claims 1-17	No			
Inventive Step (IS) Claims 1-17 NO Claims 1-17 Industrial Applicability (IA) Claims 1-17 Claims 1-17 Claims 1-17 Claims 1-17 YES Claims 1-17 Claims 1-17 Claims NONE Claims 1-17 Claims NONE Claims 1-17 lack an inventive step under PCT Article 33(3) as being obvious over CHIRON S.P.A. in view of Michon et al. CHIRON S.P.A. disclosed immunogenic compositions or vaccines comprising two or more of GBS1 through GBS689 proteins or polypeptides, including GBS80 and GBS691 proteins or polypeptides, or fragments thereof, and a streptococcal saccharide antigen. A method of making the compositions or vaccines and a method of treating an animal using the compositions or vaccines are taught. The saccharide antigen is linked to a carrier protein, such as, tetanus toxoid, diphtheria toxoid, or CRM197. CHIRON S.P.A. does not expressly teach the streptococcal saccharide antigen in the vaccine to be of GBS serotype Ia, Ib, or III. However, Michon et al. taught the use of GBS type II or III saccharide antigen conjugate vaccines and multivalent vaccines. The instant claims lack an inventive step because it would have been obvious to one of ordinary skill in the art at the time the invention was made to replace the streptococcal saccharide antigen conjugate in CHIRON S.P.As immunogenic composition or vaccinwith Michon's GBS type II or III saccharide antigen conjugate to produce the instant invention with a reasonable expectation of success. Given Michon's teaching that such saccharide antigen conjugates are usable in multivalent vaccines, which would advantageously provide GBS saccharide- and GBS protein- or polypeptide-specific immunity against multiple GBS serotypes.		ovelty (N)	Claims NONE	YES
Industrial Applicability (IA) Claims 1-17 YES Claims 1-17 lack an inventive step under PCT Article 33(3) as being obvious over CHIRON S.P.A. in view of Michon et al. CHIRON S.P.A. disclosed immunogenic compositions or vaccines comprising two or more of GBS1 through GBS689 proteins or polypeptides, including GBS80 and GBS691 proteins or polypeptides, or fragments thereof, and a streptococcal saccharide antigen. A method of making the compositions or vaccines and a method of treating an animal using the compositions or vaccines are taught. The saccharide antigen is linked to a carrier protein, such as, tetanus toxoid, diphtheria toxoid, or CRM197. CHIRON S.P.A. does not expressly teach the streptococcal saccharide antigen in the vaccine to be of GBS serotype Ia, Ib, or III. However, Michon et al. taught the use of GBS type II or III saccharide antigen covalently coupled to a bacterial carrier protein, such as, CRM197 or tetanus toxoid, in conjugate vaccines and multivalent vaccines. The instant claims lack an inventive step because it would have been obvious to one of ordinary skill in the art at the time the invention was made to replace the streptococcal saccharide antigen conjugate in CHIRON S.P.A's immunogenic composition or vaccine with Michon's GBS type II or III saccharide antigen conjugates are usable in multivalent vaccines, one of skill in the art would have been motivated to produce the instant invention for the expected benefit of producing a multivalent vaccine, which would advantageously provide GBS saccharide- and GBS protein- or polypeptide-specific immunity against multiple GBS serotypes.				
Industrial Applicability (IA) Claims 1-17 [Industrial Applicability (IA) [Indust	Īns	ventive Sten (IS)	Claims NONE	XTEQ.
Industrial Applicability (IA) Claims 1-17 Claims NONE Claims 1-17 lack an inventive step under PCT Article 33(3) as being obvious over CHIRON S.P.A. in view of Michon et al. CHIRON S.P.A. disclosed immunogenic compositions or vaccines comprising two or more of GBS1 through GBS689 proteins or polypeptides, including GBS80 and GBS691 proteins or polypeptides, or fragments thereof, and a streptococcal saccharide antigen. A method of making the compositions or vaccines and a method of treating an animal using the compositions or vaccines are taught. The saccharide antigen is linked to a carrier protein, such as, tetanus toxoid, diphtheria toxoid, or CRM197. CHIRON S.P.A. does not expressly teach the streptococcal saccharide antigen in the vaccine to be of GBS serotype Ia, Ib, or III. However, Michon et al. taught the use of GBS type II or III saccharide antigen covalently coupled to a bacterial carrier protein, such as, CRM197 or tetanus toxoid, in conjugate vaccines and multivalent vaccines. The instant claims lack an inventive step because it would have been obvious to one of ordinary skill in the art at the time the invention was made to replace the streptococcal saccharide antigen conjugate in CHIRON S.P.A's immunogenic composition or vaccine with Michon's GBS type II or III saccharide antigen conjugates are usable in multivalent vaccines, one of skill in the art would have been motivated to produce the instant invention for the expected benefit of producing a multivalent vaccine, which would advantageously provide GBS saccharide- and GBS protein- or polypeptide-specific immunity against multiple GBS serotypes.		omivo biop (15)		
Claims 1-17 lack an inventive step under PCT Article 33(3) as being obvious over CHIRON S.P.A. in view of Michon et al. CHIRON S.P.A. disclosed immunogenic compositions or vaccines comprising two or more of GBS1 through GBS689 proteins or polypeptides, including GBS80 and GBS691 proteins or polypeptides, or fragments thereof, and a streptococcal saccharide antigen. A method of making the compositions or vaccines and a method of treating an animal using the compositions or vaccines are taught. The saccharide antigen is linked to a carrier protein, such as, tetanus toxoid, diphtheria toxoid, or CRM197. CHIRON S.P.A. does not expressly teach the streptococcal saccharide antigen in the vaccine to be of GBS serotype Ia, Ib, or III. However, Michon et al. taught the use of GBS type II or III saccharide antigen covalently coupled to a bacterial carrier protein, such as, CRM197 or tetanus toxoid, in conjugate vaccines and multivalent vaccines. The instant claims lack an inventive step because it would have been obvious to one of ordinary skill in the art at the time the invention was made to replace the streptococcal saccharide antigen conjugate in CHIRON S.P.A's immunogenic composition or vaccine with Michon's GBS type II or III saccharide antigen conjugate to produce the instant invention with a reasonable expectation of success. Given Michon's teaching that such saccharide antigen conjugates are usable in multivalent vaccines, one of skill in the art would have been motivated to produce the instant invention for the expected benefit of producing a multivalent vaccine, which would advantageously provide GBS saccharide- and GBS protein- or polypeptide-specific immunity against multiple GBS serotypes.				
2. CITATIONS AND EXPLANATIONS Claims 1-17 lack an inventive step under PCT Article 33(3) as being obvious over CHIRON S.P.A. in view of Michon et al. CHIRON S.P.A. disclosed immunogenic compositions or vaccines comprising two or more of GBS1 through GBS689 proteins or polypeptides, including GBS80 and GBS691 proteins or polypeptides, or fragments thereof, and a streptococcal saccharide antigen. A method of making the compositions or vaccines and a method of treating an animal using the compositions or vaccines are taught. The saccharide antigen is linked to a carrier protein, such as, tetanus toxoid, diphtheria toxoid, or CRM197. CHIRON S.P.A. does not expressly teach the streptococcal saccharide antigen in the vaccine to be of GBS serotype Ia, Ib, or III. However, Michon et al. taught the use of GBS type II or III saccharide antigen covalently coupled to a bacterial carrier protein, such as, CRM197 or tetanus toxoid, in conjugate vaccines and multivalent vaccines. The instant claims lack an inventive step because it would have been obvious to one of ordinary skill in the art at the time the invention was made to replace the streptococcal saccharide antigen conjugate in CHIRON S.P.A's immunogenic composition or vaccine with Michon's GBS type II or III saccharide antigen conjugates are usable in multivalent vaccines, one of skill in the art would have been motivated to produce the instant invention for the expected benefit of producing a multivalent vaccine, which would advantageously provide GBS saccharide- and GBS protein- or polypeptide-specific immunity against multiple GBS serotypes.	Inc	lustrial Applicability (IA)		
Claims 1-17 lack an inventive step under PCT Article 33(3) as being obvious over CHIRON S.P.A. in view of Michon et al. CHIRON S.P.A. disclosed immunogenic compositions or vaccines comprising two or more of GBS1 through GBS689 proteins or polypeptides, including GBS80 and GBS691 proteins or polypeptides, or fragments thereof, and a streptococcal saccharide antigen. A method of making the compositions or vaccines and a method of treating an animal using the compositions or vaccines are taught. The saccharide antigen is linked to a carrier protein, such as, tetanus toxoid, diphtheria toxoid, or CRM197. CHIRON S.P.A. does not expressly teach the streptococcal saccharide antigen in the vaccine to be of GBS serotype Ia, Ib, or III. However, Michon et al. taught the use of GBS type II or III saccharide antigen covalently coupled to a bacterial carrier protein, such as, CRM197 or tetanus toxoid, in conjugate vaccines and multivalent vaccines. The instant claims lack an inventive step because it would have been obvious to one of ordinary skill in the art at the time the invention was made to replace the streptococcal saccharide antigen conjugate in CHIRON S.P.A's immunogenic composition or vaccine with Michon's GBS type II or III saccharide antigen conjugates are usable in multivalent vaccines, one of skill in the art would have been motivated to produce the instant invention for the expected benefit of producing a multivalent vaccine, which would advantageously provide GBS saccharide- and GBS protein- or polypeptide-specific immunity against multiple GBS serotypes.			Claims NONE	NO
	Claims 1-17 lac CHIR proteins or poly antigen. A meti taught. The sac CHIRON S.P.A Howe protein, such as	k an inventive step under PCT Artic ON S.P.A. disclosed immunogenic of peptides, including GBS80 and GBS had of making the compositions or vecharide antigen is linked to a carrier does not expressly teach the streptower, Michon et al. taught the use of 0, CRM197 or tetanus toxoid, in conjustant claims lack an inventive step be	ompositions or vaccines comprising two or measurements or polypeptides, or fragments the accines and a method of treating an animal usi protein, such as, tetanus toxoid, diphtheria tox coccal saccharide antigen in the vaccine to be 3BS type II or III saccharide antigen covalently gate vaccines and multivalent vaccines.	ore of GBS1 through GBS689 preof, and a streptococcal saccharide ing the compositions or vaccines are oid, or CRM197. of GBS serotype Ia, Ib, or III. y coupled to a bacterial carrier ordinary skill in the art at the time the
	invention was m with Michon's GBS type II or I Michon's teachi motivated to pro provide GBS sac	nade to replace the streptococcal sacc II saccharide antigen conjugate to pring that such saccharide antigen conjuduce the instant invention for the excharide- and GBS protein- or polyp	haride antigen conjugate in CHIRON S.P.A's coduce the instant invention with a reasonable gates are usable in multivalent vaccines, one opected benefit of producing a multivalent vacciptide-specific immunity against multiple GBS	immunogenic composition or vaccin expectation of success. Given of skill in the art would have been time, which would advantageously.
	invention was m with Michon's GBS type II or I Michon's teachin notivated to pro provide GBS sac	nade to replace the streptococcal sacc II saccharide antigen conjugate to pring that such saccharide antigen conjuduce the instant invention for the excharide- and GBS protein- or polyp	haride antigen conjugate in CHIRON S.P.A's coduce the instant invention with a reasonable gates are usable in multivalent vaccines, one opected benefit of producing a multivalent vacciptide-specific immunity against multiple GBS	immunogenic composition or vaccin expectation of success. Given of skill in the art would have been tine, which would advantageously
	invention was m with Michon's GBS type II or I Michon's teachin motivated to proprovide GBS sac	nade to replace the streptococcal sacc II saccharide antigen conjugate to pring that such saccharide antigen conjuduce the instant invention for the excharide- and GBS protein- or polyp	haride antigen conjugate in CHIRON S.P.A's coduce the instant invention with a reasonable gates are usable in multivalent vaccines, one opected benefit of producing a multivalent vacciptide-specific immunity against multiple GBS	immunogenic composition or vaccir expectation of success. Given of skill in the art would have been
	invention was m with Michon's GBS type II or I Michon's teachin motivated to proprovide GBS sac	nade to replace the streptococcal sacc II saccharide antigen conjugate to pring that such saccharide antigen conjuduce the instant invention for the excharide- and GBS protein- or polyp	haride antigen conjugate in CHIRON S.P.A's coduce the instant invention with a reasonable gates are usable in multivalent vaccines, one opected benefit of producing a multivalent vacciptide-specific immunity against multiple GBS	immunogenic composition or vaccin expectation of success. Given of skill in the art would have been tine, which would advantageously
	invention was m with Michon's GBS type II or I Michon's teachi motivated to pro provide GBS sac	nade to replace the streptococcal sacc II saccharide antigen conjugate to pring that such saccharide antigen conjuduce the instant invention for the excharide- and GBS protein- or polyp	haride antigen conjugate in CHIRON S.P.A's coduce the instant invention with a reasonable gates are usable in multivalent vaccines, one opected benefit of producing a multivalent vacciptide-specific immunity against multiple GBS	immunogenic composition or vaccin expectation of success. Given of skill in the art would have been time, which would advantageously.
	invention was m with Michon's GBS type II or I Michon's teachin motivated to proprovide GBS sac	nade to replace the streptococcal sacc II saccharide antigen conjugate to pring that such saccharide antigen conjuduce the instant invention for the excharide- and GBS protein- or polyp	haride antigen conjugate in CHIRON S.P.A's coduce the instant invention with a reasonable gates are usable in multivalent vaccines, one opected benefit of producing a multivalent vacciptide-specific immunity against multiple GBS	immunogenic composition or vaccin expectation of success. Given of skill in the art would have been time, which would advantageously.
	invention was m with Michon's GBS type II or I Michon's teachi motivated to pro provide GBS sac	nade to replace the streptococcal sacc II saccharide antigen conjugate to pring that such saccharide antigen conjuduce the instant invention for the excharide- and GBS protein- or polyp	haride antigen conjugate in CHIRON S.P.A's coduce the instant invention with a reasonable gates are usable in multivalent vaccines, one opected benefit of producing a multivalent vacciptide-specific immunity against multiple GBS	immunogenic composition or vaccin expectation of success. Given of skill in the art would have been time, which would advantageously.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/29167

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 39/385, 39/02, 39/09, 39/00					
US CL: 424/197.11, 234.1, 244.1, 184.1, 236.1, 831 According to International Patent Classification (IPC) or to both national classification and IPC					
R. FIELDS SEARCHED					
	cumentation searched (classification system followed	by classification symbols)			
	24/197.11, 234.1, 244.1, 184.1, 236.1, 831	oy oldismidaden symbolo,			
Documentation	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
	Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
C. DOC	UMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.		
Y	WO 02/34771 A2 (CHIRON S.P.A.) 02 May 2002	(02.05.2002), pages 7, 841 and 842.	1-17		
Y	US 6,372,222 B1 (MICHON et al) 16 April 2002 (16.04.2002), claims and Examples.	1-17		
Y	US 6,426,074 B1 (MICHEL et al.) 30 July 2002 (3	0.06.2002), Example 14.	1-17		
Further	r documents are listed in the continuation of Box C.	See patent family annex.			
"A" documen be of par	pecial categories of cited documents: t defining the general state of the art which is not considered to ticular relevance plication or patent published on or after the international filing	"T" later document published after the in priority date and not in conflict with understand the principle or theory ur document of particular relevance; the considered novel or cannot be considered."	the application but cited to derlying the invention		
	t which may throw doubts on priority claim(s) or which is cited ish the publication date of another citation or other special reason fied)	"Y" document of particular relevance; the considered to involve an inventive st combined with one or more other suc	e claimed invention cannot be ep when the document is		
	t referring to an oral disclosure, use, exhibition or other means	combination being obvious to a person	on skilled in the art		
	t published prior to the international filing date but later than the	"&" document member of the same patent			
	date claimed actual completion of the international search	Date of mailing of the international sea	02°AUG 2004		
15 April 200	4 (15.04.2004)				
Ma Co	railing address of the ISA/US il Stop PCT, Attn: ISA/US mmissioner for Patents D. Box 1450	S. Devi, Ph.D.	to-fly		
ł	exandria, Virginia 22313-1450 o. (703)305-3230	Telephone No. (703) 308-0196			

Form FCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US03/29167

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet
1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

	PCT/US03/29167
INTERNATIONAL SEARCH REPORT	
	1
BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LAC	CKING
This application contains claims directed to more than one species of the generic	invention. These species are deemed to lack unity of
invention because they are not so linked as to form a single general inventive con-	cept under PCT Rule 13.1.
In order for more than one species to be examined, the appropriate additional examined,	mination fees must be paid. The species are as
follows:	
GBS saccharide antigen species: serotype Ia; serotype Ib; and serotype III.	
The claims are deemed to correspond to the species listed above in the following a	monmon.
Claims 1 and 17.	manner.
The species listed above do not relate to a single general inventive concept under	PCT Rule 13.1 because under PCT Rule 13.2, the
species lack the same or corresponding special technical features for the following	reasons:
The saccharide antigen species listed above do not share significant struc	ctural elements and immunogenici specificity.
	,
	•
Continuation of B. FIELDS SEARCHED Item 3:	
DIALOG, WEST, EMBASE, BIOSIS, MEDLINE	·
GBS or group B streptococc?, (Ia or Ib or III), GBS79, GBS80 to GBS 691, invent	tor's name

Form FCT/ISA/210 (second sheet) (July 1998)